New hope for kids with tough cancers: drug combo trial launches

NCT ID NCT05004116

Recruiting now Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new cancer drug, repotrectinib, combined with standard chemotherapy in children and young adults with advanced solid tumors that have spread. The goal is to find the safest dose and see if the combination can shrink tumors. Researchers will also study how the body processes the drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Repotrectinib (a targeted cancer drug) combined with chemotherapy (irinotecan and temozolomide)
What this could lead to: If it works, this could offer a new treatment option for children and young adults with hard-to-treat solid tumors that have spread.
What could go wrong: This is an early-phase trial (Phase 1/2) with only 77 participants, so the combination may not prove effective or safe for broader use. Side effects from the drugs could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer desmoplastic small round cell tumor diffuse intrinsic pontine glioma metastatic malignant neoplasm neoplasm Neoplasm Metastasis neuroblastoma, susceptibility to, 3 primary brain neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CANCER METASTATIC SOLID TUMOR

Contacts and locations

Locations

Memorial Sloan Kettering Cancer Center (All Protocol Activities)
RECRUITING

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.